

# Nicola Hewitt

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2895456/nicola-hewitt-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53  
papers

3,058  
citations

23  
h-index

53  
g-index

53  
ext. papers

3,517  
ext. citations

3.5  
avg, IF

4.39  
L-index

#	Paper	IF	Citations
53	A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment.. <i>Regulatory Toxicology and Pharmacology</i> , <b>2022</b> , 129, 105094	3.4	2
52	Use of in vitro metabolism and biokinetics assays to refine predicted in vivo and in vitro internal exposure to the cosmetic ingredient, phenoxyethanol, for use in risk assessment.. <i>Regulatory Toxicology and Pharmacology</i> , <b>2022</b> , 105132	3.4	0
51	Read-across and new approach methodologies applied in a 10-step framework for cosmetics safety assessment - A case study with parabens.. <i>Regulatory Toxicology and Pharmacology</i> , <b>2022</b> , 105161	3.4	0
50	Use of Physiologically-Based Kinetics Modelling to Reliably Predict Internal Concentrations of the UV Filter, Homosalate, After Repeated Oral and Topical Application.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 802514	5.6	0
49	Validation of the 3D reconstructed human skin Comet assay, an animal-free alternative for following-up positive results from standard in vitro genotoxicity assays. <i>Mutagenesis</i> , <b>2021</b> , 36, 19-35	2.8	14
48	Metabolism and plasma protein binding of 16 straight- and branched-chain parabens in in vitro liver and skin models. <i>Toxicology in Vitro</i> , <b>2021</b> , 72, 105051	3.6	0
47	Characterization of application scenario-dependent pharmacokinetics and pharmacodynamic properties of permethrin and hyperforin in a dynamic skin and liver multi-organ-chip model. <i>Toxicology</i> , <b>2021</b> , 448, 152637	4.4	11
46	Demonstration of the first-pass metabolism in the skin of the hair dye, 4-amino-2-hydroxytoluene, using the Chip2 skin-liver microphysiological model. <i>Journal of Applied Toxicology</i> , <b>2021</b> , 41, 1553-1567	4.1	5
45	New framework for a non-animal approach adequately assures the safety of cosmetic ingredients - A case study on caffeine. <i>Regulatory Toxicology and Pharmacology</i> , <b>2021</b> , 123, 104931	3.4	4
44	Cosmetics Europe evaluation of 6 in silico skin penetration models. <i>Computational Toxicology</i> , <b>2021</b> , 19, 100177	3.1	2
43	Validation of the 3D reconstructed human skin micronucleus (RSMN) assay: an animal-free alternative for following-up positive results from standard in vitro genotoxicity assays. <i>Mutagenesis</i> , <b>2021</b> , 36, 1-17	2.8	7
42	Comparison of the metabolism of 10 cosmetics-relevant chemicals in EpiSkin <sup>TM</sup> 9 subcellular fractions and in vitro human skin explants. <i>Journal of Applied Toxicology</i> , <b>2020</b> , 40, 313-326	4.1	4
41	Use of human liver and EpiSkin <sup>TM</sup> 9 subcellular fractions as a screening assays to compare the in vitro hepatic and dermal metabolism of 47 cosmetics-relevant chemicals. <i>Journal of Applied Toxicology</i> , <b>2020</b> , 40, 416-433	4.1	8
40	Measurement of the penetration of 56 cosmetic relevant chemicals into and through human skin using a standardized protocol. <i>Journal of Applied Toxicology</i> , <b>2020</b> , 40, 403-415	4.1	18
39	Partition coefficient and diffusion coefficient determinations of 50 compounds in human intact skin, isolated skin layers and isolated stratum corneum lipids. <i>Toxicology in Vitro</i> , <b>2020</b> , 69, 104990	3.6	7
38	Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop. <i>Regulatory Toxicology and Pharmacology</i> , <b>2019</b> , 103, 63-72	3.4	15
37	Road Map for Development of Stem Cell-Based Alternative Test Methods. <i>Trends in Molecular Medicine</i> , <b>2019</b> , 25, 470-481	11.5	19

36	Use of a Simple in vitro Test to Assess Loss of Chemical due to Volatility during an in vitro Human Skin Absorption Study. <i>Skin Pharmacology and Physiology</i> , <b>2019</b> , 32, 117-124	3	5
35	Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model. <i>Xenobiotica</i> , <b>2019</b> , 49, 22-35	2	8
34	Comparison of the metabolism of 10 chemicals in human and pig skin explants. <i>Journal of Applied Toxicology</i> , <b>2019</b> , 39, 385-397	4.1	20
33	A strategy for systemic toxicity assessment based on non-animal approaches: The Cosmetics Europe Long Range Science Strategy programme. <i>Toxicology in Vitro</i> , <b>2018</b> , 50, 137-146	3.6	31
32	Comparison of the Skin Penetration of 3 Metabolically Stable Chemicals Using Fresh and Frozen Human Skin. <i>Skin Pharmacology and Physiology</i> , <b>2017</b> , 30, 234-245	3	14
31	Extrapolation of systemic bioavailability assessing skin absorption and epidermal and hepatic metabolism of aromatic amine hair dyes in vitro. <i>Toxicology and Applied Pharmacology</i> , <b>2015</b> , 287, 139-148 <sup>6</sup>	4.6	15
30	Cryopreservation of Hepatocytes. <i>Methods in Molecular Biology</i> , <b>2015</b> , 1250, 13-26	1.4	6
29	A novel strategy for ADME screening of prodrugs: combined use of serum and hepatocytes to integrate bioactivation and clearance, and predict exposure to both active and prodrug to the systemic circulation. <i>Journal of Pharmaceutical Sciences</i> , <b>2014</b> , 103, 1504-14	3.9	6
28	The Cosmetics Europe strategy for animal-free genotoxicity testing: project status up-date. <i>Toxicology in Vitro</i> , <b>2014</b> , 28, 18-23	3.6	44
27	Dermal xenobiotic metabolism: a comparison between native human skin, four in vitro skin test systems and a liver system. <i>Skin Pharmacology and Physiology</i> , <b>2014</b> , 27, 263-75	3	35
26	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. <i>Archives of Toxicology</i> , <b>2013</b> , 87, 1315-530	5.8	837
25	Evaluation of chemicals requiring metabolic activation in the EpiDerm™BD human reconstructed skin micronucleus (RSMN) assay. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , <b>2013</b> , 750, 40-9	3	26
24	Use of human in vitro skin models for accurate and ethical risk assessment: metabolic considerations. <i>Toxicological Sciences</i> , <b>2013</b> , 133, 209-17	4.4	79
23	Xenobiotic metabolism capacities of human skin in comparison with a 3D-epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: phase II enzymes. <i>Experimental Dermatology</i> , <b>2012</b> , 21, 364-9	4	66
22	Xenobiotic metabolism capacities of human skin in comparison with a 3D epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: activating enzymes (Phase I). <i>Experimental Dermatology</i> , <b>2012</b> , 21, 358-63	4	91
21	Generation of proliferating human hepatocytes using Upcyte™ technology: characterisation and applications in induction and cytotoxicity assays. <i>Xenobiotica</i> , <b>2012</b> , 42, 939-56	2	49
20	Effects of the genotoxic compounds, benzo[a]pyrene and cyclophosphamide on phase 1 and 2 activities in EpiDerm™ models. <i>Xenobiotica</i> , <b>2012</b> , 42, 526-37	2	13
19	The reconstructed skin micronucleus assay (RSMN) in EpiDerm™ detailed protocol and harmonized scoring atlas. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , <b>2011</b> , 720, 42-52	3	34

18	International prevalidation studies of the EpiDerm 3D human reconstructed skin micronucleus (RSMN) assay: transferability and reproducibility. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , <b>2010</b> , 701, 123-31	3	46
17	A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: genotoxicity. A COLIPA analysis. <i>Regulatory Toxicology and Pharmacology</i> , <b>2010</b> , 57, 315-24	3.4	50
16	Optimisation of the cryopreservation of primary hepatocytes. <i>Methods in Molecular Biology</i> , <b>2010</b> , 640, 83-105	1.4	16
15	Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. <i>Xenobiotica</i> , <b>2009</b> , 39, 656-62	2	25
14	Skin metabolism of aminophenols: human keratinocytes as a suitable in vitro model to qualitatively predict the dermal transformation of 4-amino-2-hydroxytoluene in vivo. <i>Toxicology and Applied Pharmacology</i> , <b>2009</b> , 235, 114-23	4.6	45
13	A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: skin irritation. <i>Regulatory Toxicology and Pharmacology</i> , <b>2009</b> , 54, 188-96	3.4	29
12	Metabolite screening of aromatic amine hair dyes using in vitro hepatic models. <i>Xenobiotica</i> , <b>2009</b> , 39, 811-25	2	13
11	Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. <i>Drug Metabolism Reviews</i> , <b>2007</b> , 39, 159-234	7	575
10	Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. <i>Xenobiotica</i> , <b>2007</b> , 37, 1196-224	2	150
9	Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?. <i>Chemico-Biological Interactions</i> , <b>2007</b> , 168, 51-65	5	67
8	Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations. <i>Journal of Pharmacy and Pharmacology</i> , <b>2006</b> , 58, 633-41	4.8	54
7	The effect of EGF and the comitogen, norepinephrine, on the proliferative responses of fresh and cryopreserved rat and mouse hepatocytes. <i>Cryobiology</i> , <b>2006</b> , 53, 182-93	2.7	10
6	Phase I and II enzyme characterization of two sources of HepG2 cell lines. <i>Xenobiotica</i> , <b>2004</b> , 34, 243-56	2	138
5	Cryopreserved rat, dog and monkey hepatocytes: measurement of drug metabolizing enzymes in suspensions and cultures. <i>Human and Experimental Toxicology</i> , <b>2004</b> , 23, 307-16	3.4	18
4	New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. <i>Drug Metabolism Reviews</i> , <b>2003</b> , 35, 145-213	7	222
3	Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. <i>Chemico-Biological Interactions</i> , <b>2002</b> , 142, 73-82	5	29
2	Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. <i>Drug Metabolism and Disposition</i> , <b>2001</b> , 29, 1042-50	4	56
1	Metabolic activity of fresh and cryopreserved cynomolgus monkey ( <i>Macaca fascicularis</i> ) hepatocytes. <i>Xenobiotica</i> , <b>2000</b> , 30, 665-81	2	20

